ArticleJournal of clinical medicine2026
Association Between Body Mass Index and Clinical Outcomes of CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer: A Real-World Cohort Study.
Seval Orman et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.